Genmab — Januar 2020
-
-
The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors - https://www.mdpi.com/2073-4409/9/1/52
-
ØU sælger Genmab fra i porteføljen
-
ØUs begrundelse: Genmab ramte toppen i begyndelsen af december, og kursfaldet er fortsat ind i det nye år. Vi skiller os derfor af med aktien, og afventer en ny optimisme inden et eventuelt genkøb.
-
Der har også siden opturen været 6-7 nyheder, hvoraf 4 er insidersalg, så Genmab ber selv om det, det er og bliver aldrig en folkeaktie, så vi skal sørge for at fejre det hver gang den topper da det maks bliver 1-2 dages fester af gangen før nye tildelinger eller salg fra den fede bestyrelse begynder............så stop dog med at give bestyrelsen aktier, giv dem et fast vederlag på 300.000 pr møde lidt sild og snaps og flyv dem hjem igen.
-
the PhII Camidanlumab trial starts to recruit in Europe (Spain) https://clinicaltrials.gov/ct2/history/NCT04052997?A=11&B=12&C=merged#StudyPageTop
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
